Drug development. Orphan drug windfalls?

Letter: "Orphan-drug" development - whose responsibility?

Rare lung disease and orphan drug development.

Diazoxide--an orphan drug?

Successful development of an orphan drug for the pediatric population.

Challenges in orphan drug development and regulatory policy in China.

From promising molecules to orphan drugs: Early clinical drug development.

The evolving drug development landscape: from blockbusters to niche busters in the orphan drug space.

Creating the costliest orphan. The Orphan Drug Act in the development of Ceredase.

Editorial: Orphan GPCRs As Emerging Drug Targets.

A new kind of orphan drug?

Bush veto fuels orphan drug act uncertainties.

Judge upends 340B orphan drug exclusion.

Orphan Drug Act. Winners to keep all.

EU and in Latin America.

Pressure for drug development in lysosomal storage disorders - a quantitative analysis thirty years beyond the US orphan drug act.

Some Numbers behind Canada's Decision to Adopt an Orphan Drug Policy: US Orphan Drug Approvals in Canada, 1997-2012.

The current status of orphan drug development in Europe and the US.

Clinical trial transparency and orphan drug development: recent trends in data sharing by the pharmaceutical industry.

New Financial and Research Models for Pediatric Orphan Drug Development - Focus on the NCATS TRND Program.

Development of chidamide for peripheral T-cell lymphoma, the first orphan drug approved in China.

Development of an orphan drug by a start-up company. MetroGel for rosacea.

Insurance companies' perspectives on the orphan drug pipeline.

Brand-name drug, generic drug, orphan drug. Pharmacological therapy with biosimilar drugs - provision of due diligence in the treatment process.

New cystic fibrosis drug paves the way for orphan diseases.

Suggest Documents

Letter: "Orphan-drug" development - whose responsibility?

Rare lung disease and orphan drug development.

Diazoxide--an orphan drug?

Successful development of an orphan drug for the pediatric population.

Challenges in orphan drug development and regulatory policy in China.

From promising molecules to orphan drugs: Early clinical drug development.

The evolving drug development landscape: from blockbusters to niche busters in the orphan drug space.

Creating the costliest orphan. The Orphan Drug Act in the development of Ceredase.

Editorial: Orphan GPCRs As Emerging Drug Targets.

A new kind of orphan drug?

Bush veto fuels orphan drug act uncertainties.

Judge upends 340B orphan drug exclusion.

Orphan Drug Act. Winners to keep all.

EU and in Latin America.

Pressure for drug development in lysosomal storage disorders - a quantitative analysis thirty years beyond the US orphan drug act.

Some Numbers behind Canada's Decision to Adopt an Orphan Drug Policy: US Orphan Drug Approvals in Canada, 1997-2012.

The current status of orphan drug development in Europe and the US.

Clinical trial transparency and orphan drug development: recent trends in data sharing by the pharmaceutical industry.

New Financial and Research Models for Pediatric Orphan Drug Development - Focus on the NCATS TRND Program.

Development of chidamide for peripheral T-cell lymphoma, the first orphan drug approved in China.

Development of an orphan drug by a start-up company. MetroGel for rosacea.

Insurance companies' perspectives on the orphan drug pipeline.

Brand-name drug, generic drug, orphan drug. Pharmacological therapy with biosimilar drugs - provision of due diligence in the treatment process.

New cystic fibrosis drug paves the way for orphan diseases.

Drug development. Orphan drug windfalls?

Recommend Documents

Follow Us